Evidence map›Paper›PMID 37032736›Full record

ArticleHarvard data science review2022

Accommodating Serial Correlation and Sequential Design Elements in Personalized Studies and Aggregated Personalized Studies.

Nicholas J Schork

Abstract read
In one paragraph

Article in Harvard data science review, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Exploring human biology with N-of-1 clinical trials.Cambridge prisms. Precision medicine · 2023
    Article
  7. Does Modulation of an Epigenetic Clock Define a Geroprotector?Advances in geriatric medicine and research · 2022
    Article
  8. Article
  9. The Family of Single-Case Experimental Designs.Harvard data science review · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Nicholas J SchorkThe Translational Genomics Research Institute (TGen), an affiliate of the City of Hope National Medical Center; The University of California San Diego; and Scripps Research.

Funding

Systems BiologyU19AG023122 · NIA · TRANSLATIONAL GENOMICS RESEARCH INST · PI Thomas Girke, NICHOLAS Joseph SCHORK · 2004 to 2026
$102.6M
Regulatory and Human Study Operations (RHSO) Core CU19AG065169 · NIA · UNIVERSITY OF ARIZONA · PI SCHORK, NICHOLAS JOSEPH · 2021 to 2025
$59.8M
Re-engineering Precision Therapeutics Through N-of-1 TrialsR01LM012836 · NLM · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI DAVIDSON, KARINA W. · 2017 to 2023
$7.6M
Roybal Center for Personalized Trials: Physical Activity Promotion to Foster Healthy AgingP30AG063786 · NIA · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI Karina W. Davidson · 2020 to 2026
$6.7M
Integrative Resource to Develop Translational Strategies to Promote LongevityU24AG051129 · NIA · CALIFORNIA PACIFIC MED CTR RES INSTITUTE · PI CUMMINGS, STEVEN RON, EVANS, DANIEL SPENCER · 2015 to 2019
$5.3M
Integrative Omics to enhance therapeutics development for healthy agingUH3AG064706 · NIA · TRANSLATIONAL GENOMICS RESEARCH INST · PI MILLER, RICHARD A, SCHORK, NICHOLAS JOSEPH · 2021 to 2024
$3.3M
Integrative Omics to enhance therapeutics development for healthy agingUH2AG064706 · NIA · TRANSLATIONAL GENOMICS RESEARCH INST · PI EVANS, DANIEL SPENCER, MILLER, RICHARD A · 2019 to 2020
$1.4M
NIA NIH HHS P30 AG063786NIA NIH HHS U19 AG023122NIA NIH HHS U19 AG065169NIA NIH HHS U24 AG051129NIA NIH HHS UH2 AG064706NIA NIH HHS UH3 AG064706NLM NIH HHS R01 LM012836
6 · The paper itself

Abstract

Single subject, or 'N-of-1,' studies are receiving a great deal of attention from both theoretical and applied researchers. This is consistent with the growing acceptance of 'personalized' approaches to health care and the need to prove that personalized interventions tailored to an individual's likely unique physiological profile and other characteristics work as they should. In fact, the preferred way of referring to N-of-1 studies in contemporary settings is as 'personalized studies.' Designing efficient personalized studies and analyzing data from them in ways that ensure statistically valid inferences are not trivial, however. I briefly discuss some of the more complex issues surrounding the design and analysis of personalized studies, such as the use of washout periods, the frequency with which measures associated with the efficacy of an intervention are collected during a study, and the serious effect that serial correlation can have on the analysis and interpretation of personalized study data and results if not accounted for explicitly. I point out that more efficient sequential designs for personalized and aggregated personalized studies can be developed, and I explore the properties of sequential personalized studies in a few settings via simulation studies. Finally, I comment on contexts within which personalized studies will likely be pursued in the future.

Indexed as

drug developmentprecision medicinesequential analysisserial correlation

Identifiers

PMID37032736
PMCPMC10081537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.